Dr. Is In Sessions
Monday, May 2, 2022
Understanding long-term Gene and Cell Therapy investment complexities requires a keen awareness of where the science and the markets are headed. That’s why “The Doctor is In” in these updates on the latest GCT technologies. Presented by Mass General Brigham clinicians and innovators from the front lines of care, the sessions are co-hosted by expert analysts from Bank of America and include interactive discussion and Q&A.
-
Gene and Epigenetic Editing in the Development of Treatment for Deafness
11:45 AM – 12:45 PM View HereIn this session, Dr. Edge will discuss how deafness is treated by drugs and gene editing approaches using targets discovered in cochlear organoids.
- Moderator:
-
- Geoff Meacham, PhD
-
- Managing Director, Global Research, BofA Securities
- Panelist:
-
- Albert Edge, PhD
-
- Eaton Peabody Professor of Otolaryngology, HMS, Mass Eye and Ear
-
Single Gene Correction in the Brain: Delivering Where it Matters Most
11:45 AM – 12:45 PM View HereIn this session, Dr. Eichler will discuss the impact of gene defects across the lifespan and how timing and delivery of new genetic therapies is transforming the field of neurogenetics.
- Panelist:
-
- Florian Eichler, MD
-
- Director, Center for Rare Neurological Diseases, MGH
- Associate Professor of Neurology, HMS
-
Repair, Replace, Regrow: The Advancement of Regenerative Medicine
11:45 AM – 12:45 PM View HereIn this session, hear from experts in their field as they discuss the need and importance of regenerative medicine for the advancement in the treatment of diseases such as diabetes, kidney disease and blood disorders.
- Moderator:
-
- Jason Zemansky, PhD
-
- Vice President, Global Research, BofA Securities
- Panelist:
-
- Joseph Bonventre, MD, PhD
-
- Chief, Division of Renal Medicine, BWH
- Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair, HMS
- David Scadden, MD
-
- Director, Center for Regenerative Medicine, MGH
- Gerald and Darlene Jordan Professor of Medicine, HMS
-
Smart Materials: Non-viral Vectors for Gene Therapy
11:45 AM – 12:45 PM View HereIn this session, Dr. Artzi will share how an integrative approach of combining materials science, chemistry, imaging, and biology enables targeted delivery of gene therapy.
- Moderator:
-
- Alec Stranahan, PhD
-
- Vice President, Equity Research, BofA Securities
- Panelist:
-
- Natalie Artzi, PhD
-
- Assistant Professor of Medicine, HMS
-
Newborn Sequencing and Prevention of Rare Diseases: A New Public Health and Biopharma Challenge
11:45 AM – 12:45 PM View HereIn this session, Drs. Robert Green and Adam Shaywitz will discuss how the early detection and prevention of rare diseases is imminent and represents an enormous public health opportunity.
- Moderator:
-
- Jason Gerberry
-
- Managing Director, Global Research, BofA Securities
- Panelists:
-
- Robert Green, MD
-
- Director, Genomes2People Research Program, BWH
- Professor of Medicine, HMS
- Adam Shaywitz, MD, PhD
-
- CMO, BridgeBio Gene Therapy
-
Leveraging Novel Mechanisms for Accelerated Vaccine and Immunotherapy Development
11:45 AM – 12:45 PM View HereIn this session, Dr. Poznansky will share how research and development of vaccines and immunotherapy are safely accelerated from research lab to the patient leveraging novel mechanisms.
- Moderator:
-
- Alexandria Hammond, PhD
-
- Associate, Global Research, BofA Securities
- Panelist:
-
- Mark Poznansky, MD, PhD
-
- Director, Vaccine and Immunotherapy Center, MGH
- Professor of Medicine, HMS